NCT03596840

Brief Summary

This study evaluates the effectiveness of different anti-hypertensive drugs on patients with hypertension and microalbuminuria.

Trial Health

35
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
3,000

participants targeted

Target at P75+ for all trials

Timeline
Completed

Started Aug 2018

Typical duration for all trials

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

July 13, 2018

Completed
11 days until next milestone

First Posted

Study publicly available on registry

July 24, 2018

Completed
8 days until next milestone

Study Start

First participant enrolled

August 1, 2018

Completed
2 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

July 31, 2020

Completed
5 months until next milestone

Study Completion

Last participant's last visit for all outcomes

December 31, 2020

Completed
Last Updated

July 26, 2018

Status Verified

July 1, 2018

Enrollment Period

2 years

First QC Date

July 13, 2018

Last Update Submit

July 24, 2018

Conditions

HypertensionMicroalbuminuria

Keywords

HypertensionMicroalbuminuriaEffectivenessAntihypertensive medications

Outcome Measures

Primary Outcomes (1)

  • Urine Albumin-to-Creatinine Ratio (UCAR)

    Differences in UCAR between with ACEI/ARB and without ACEI/ARB

    12 months

Secondary Outcomes (1)

  • Combined endpoints: re-admission, cardiovascular events, and all-cause mortality

    12 months

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodProbability Sample
Study Population

Community Hypertensive Patients With Microalbuminuria

You may qualify if:

  • Patients with essential hypertension;
  • Urinary albumin/creatinine ratio in random urine samples is 30-300 mg/g
  • Age \>=18
  • Understand and sign informed consent

Contact the study team to confirm eligibility.

Sponsors & Collaborators

MeSH Terms

Conditions

Hypertension

Condition Hierarchy (Ancestors)

Vascular DiseasesCardiovascular Diseases

Central Study Contacts

Xuejuan Jin, MS

CONTACT

+86-13681973269jin.xuejuan@zs-hospital.sh.cn

Wei Zhang, phD

CONTACT

+86-13917535963

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Associate Professor

Study Record Dates

First Submitted

July 13, 2018

First Posted

July 24, 2018

Study Start

August 1, 2018

Primary Completion

July 31, 2020

Study Completion

December 31, 2020

Last Updated

July 26, 2018

Record last verified: 2018-07